NEM vs NEU
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Newmont Corporation presents a dichotomy between strong operational fundamentals and significant valuation premiums. While the Piotroski F-Score of 4/9 indicates stable health and the balance sheet is pristine with a Debt/Equity ratio of 0.17, the stock trades at a substantial premium to its Graham Number ($66.88) and Intrinsic Value ($44.73). Recent quarterly earnings beats are impressive, yet bearish insider sentiment and a 0/100 technical trend suggest a lack of immediate conviction from internal stakeholders and market momentum. The overall outlook is neutral as strong profitability is offset by overvaluation and negative insider signals.
NEU exhibits strong fundamental health with a Piotroski F-Score of 7/9 and robust liquidity, but it is currently trading at a significant premium to its deterministic value. The current price of $675.62 far exceeds both the Graham Number ($430.75) and the growth-based Intrinsic Value ($306.46). While profitability remains high with an ROE of 25.27%, the company is facing a growth contraction with negative YoY revenue and earnings growth. Consequently, the stock appears overvalued despite its operational quality.
Compare Another Pair
Related Comparisons
NEM vs NEU: Head-to-Head Comparison
This page compares Newmont Corporation (NEM) and NewMarket Corporation (NEU) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.